Towards dynamic metabolic flux analysis in CHO cell cultures
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Chinese hamster ovary (CHO) cells are the most widely used mammalian cell line for biopharmaceutical production, with a total global market approaching $100 billion per year. In the pharmaceutical industry CHO cells are grown in fed‐batch culture, where cellular metabolism is characterized by high glucose and glutamine uptake rates combined with high rates of ammonium and lactate secretion. The metabolism of CHO cells changes dramatically during a fed‐batch culture as the cells adapt to a changing environment and transition from exponential growth phase to stationary phase. Thus far, it has been challenging to study metabolic flux dynamics in CHO cell cultures using conventional metabolic flux analysis techniques that were developed for systems at metabolic steady state. In this paper we review progress on flux analysis in CHO cells and techniques for dynamic metabolic flux analysis. Application of these new tools may allow identification of intracellular metabolic bottlenecks at specific stages in CHO cell cultures and eventually lead to novel strategies for improving CHO cell metabolism and optimizing biopharmaceutical process performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“In cancer cells, the Warburg Effect has been attributed to the activity of an alternative splice isoform of pyruvate kinase M2-PK [56].”
BackgroundProduction of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 2×
“In addition, large bioreactors of 10 000 L or more are common these days to satisfy the growing worldwide needs for therapeutic proteins [2, 4, 5].”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“In order to reduce reactive oxygen species, it stimulates oxPPP shunt for NADPH production via TIGAR expression that activates oxPPP by inhibition of phosphofructokinase [71].”
BackgroundIsozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
Wilson, J. E. (2003) · Journal of Experimental Biology · doi:10.1242/jeb.00241 · Cited by 1,085 · cited 1×
“Hexokinase is the initial step in the conversion of glucose to glucose-6phosphate, which is a key branch point for glycolysis, pentose-phosphate pathway and glycogen storage [53].”
BackgroundWolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789 · cited 1×
“Recently, hexokinase 2 was identified as a key mediator of aerobic glycolysis [55].”
BackgroundEffects of ammonia and lactate on hybridoma growth, metabolism, and antibody production
Ozturk, S. S., Riley, M. R., & Palsson, B. O. (1992) · Biotechnology and Bioengineering · doi:10.1002/bit.260390408 · Cited by 370
Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells
Metallo, C. M., Walther, J. L., & Stephanopoulos, G. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.07.010 · Cited by 280 · cited 1×
“In some studies 5–10% serum was added to the medium [120, 121], while serum-free media containing non-animal derived hydrolysates are commonly used in the industry [122, 123].”
BackgroundLao, M.-S., & Toth, D. (1997) · Biotechnology Progress · doi:10.1021/bp9602360 · Cited by 268
Zhu, M. M., Goyal, A., Rank, D. L., Gupta, S. K., Boom, T. V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp049815s · Cited by 199
Thorens, B., & Vassalli, P. (1986) · Nature · doi:10.1038/321618a0 · Cited by 147
Grillberger, L., Kreil, T. R., Nasr, S., & Reiter, M. (2009) · Biotechnology Journal · doi:10.1002/biot.200800241 · Cited by 144
Cited by
Deuterium‐ and Tritium‐Labelled Compounds: Applications in the Life Sciences
Atzrodt, J., Derdau, V., Kerr, W. J., & Reid, M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201704146 · Cited by 810
A roadmap for interpreting 13C metabolite labeling patterns from cells
Buescher, J. M., Antoniewicz, M. R., Boros, L. G., Burgess, S. C., Brunengraber, H., Clish, C. B., DeBerardinis, R. J., Feron, O., Frezza, C., Ghesquiere, B., et al. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.02.003 · Cited by 629
Self-citationRitacco, F. V., Wu, Y., & Khetan, A. (2018) · Biotechnology Progress · doi:10.1002/btpr.2706 · Cited by 273
A guide to 13C metabolic flux analysis for the cancer biologist
Antoniewicz, M. R. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0060-y · Cited by 260
Self-citationAhn, W. S., & Antoniewicz, M. R. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2012.10.001 · Cited by 160
Self-citation
Metadata
- Authors
- Ahn, W. S., & Antoniewicz, M. R.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2011-11-21
- Volume
- 7
- Issue
- 1
- Pages
- 61-74
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2150975723
- Cited by
- 119
- References
- 11
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.